Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 7, 1999, Pages 1631-1637

  Dubin, Donald T ^a   Fitzgibbon, Joseph E ^a   Nahvi, Massoumeh D ^a   John, Joseph F ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE IV; LEVOFLOXACIN; METICILLIN; OXACILLIN; QUINOLONE DERIVATIVE; SPARFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DNA SEQUENCE; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA SEQUENCE; SEQUENCE ANALYSIS; SPECIES DIFFERENCE; STAPHYLOCOCCUS HAEMOLYTICUS;

EID: 0032779412     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.7.1631     Document Type: Article

References (43)

1. Acar, J. F., and F. W. Goldstein. 1997. Trends in bacterial resistance to fluoroquinolones. Clin. Infect. Dis. 24(Suppl. 1):S67-S73.
2. Archer, G. L., and M. W. Climo. 1994. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob. Agents Chemother. 38:2231-2237.
3. Bannerman, T. L., D. L. Wadiak, and W. E. Kloos. 1991. Susceptibility of Staphylococcus species and subspecies to fleroxacin. Antimicrob. Agents Chemother. 35:2135-2139.
4. Blumberg, H. M., D. Rimland, D. J. Carroll, P. Terry, and I. K. Wachsmuth. 1991. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J. Infect. Dis. 163:1279-1285.
5. Brighty, K. E., and T. D. Gootz. 1997. The chemistry and biological profile of trovafloxacin. J. Antimicrob. Chemother. 39(Suppl. B):1-14.
6. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
7. Dubin, D. T., J. E. Fitzgibbon, and J. L. John. 1998. Unpublished observations.
8. Dubin, D. T., J. E. Fitzgibbon, and J. F. John. 1998. Topoisomerase mutations in fluoroquinolone (Fq)-resistant coagulase-negative staphylococci (CNS), abstr. C-44, p. 81. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Entenza, J. M., O. Marchetti, M. P. Glauser, and P. Moreillon. 1998. Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. Antimicrob. Agents Chemother. 42:1889-1894.
10. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
11. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653.
12. Fitzgibbon, J. E., J. F. John, J. L. Delucia, and D. T. Dubin. 1998. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2122-2124.
13. Fuchs, P. C., A. L. Barry, and S. D. Brown. 1999. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the Irovafloxacin disk test. Diagn. Microbiol. Infect. Dis. 33:33-38.
14. Fukuda, H., S. Hori, and K. Hiramatsu. 1998. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob. Agents Chemother. 42:1917-1922.
15. Gribaldo, S., B. Cookson, N. Saunders, R. Marples, and J. Stanley. 1997. Rapid identification by specific PCR of coagulase-negative staphylococcal species important in hospital infection. J. Med. Microbiol. 46:45-53.
16. Guillemin, I., V. Jarlier, and E. Cambau. 1998. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob. Agents Chemother. 42:2084-2088.
17. Hallett, P., and A. Maxwell. 1991. Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: enzymatic analysis of the mutant proteins. Antimicrob. Agents Chemother. 35:335-340.
18. Heisig, P., B. Kratz, E. Halle, Y. Graser, M. Altwegg, W. Rabsch, and J. P. Faber. 1995. Identification of DNA gyrase A mutations in ciprofloxacin-resistant isolates of Salmonella typhimurium from men and cattle in Germany. Microb. Drug Resist. 1:211-218.
19. Hooper, D. C. 1998. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin. Infect. Dis. 27:S54-S63.
20. Jones, R. N. 1994. Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods. Diagn. Microbiol. Infect. Dis. 20:167-170.
21. Jones, R. N., A. L. Barry, R. V. Gardiner, and R. R. Packer. 1989. The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective national surveillance trial of isolates from 40 medical centers. Diagn. Microbiol. Infect. Dis. 12:385-394.
22. Kloos, W. 1997. Taxonomy and systematics of staphylococci indigenous to humans, p. 113-137. In J. B. Crossley and G. L. Archer (ed.), The staphylococci in human disease. Churchill Livingstone, New York, N.Y.
23. Kloos, W. E., C. G. George, J. S. Olgiate, L. Vanpelt, M. L. Mckinnon, B. L. Zimmer, E. Muller, M. P. Weinstein, and S. Mirrett. 1998. Staphylococcus hominis subsp. novobiosepticus, a novel trehalose- and N-acetyl-D-glucosamine-negative, novobiocin- and multiple-antibiotic-resistant subspecies isolated from human blood cultures. Int. J. Syst. Bacteriol. 48:799-812.
24. Kunst, F., N. Ogasawara, I. Moszer, A. M. Albertini, G. Alloni, V. Azevedo, M. G. Bertero, P. Bessieres, A. Bolotin, S. Borchert, R. Borriss, L. Boursier, A. Brans, M. Braun, S. C. Brignell, S. Bron, S. Brouillet, C. V. Bruschi, B. Caldwell, V. Capuano, N. M. Carter, S. K. Choi, J. J. Codani, I. F. Connerton, and A. Danchin. 1997. The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature 390:249-256.
25. Laverdiere, M., K. Weiss, R. Rivest, and J. Delorme. 1998. Trends in antibiotic resistance of staphylococci over an eight-year period - differences in the emergence of resistance between coagulase-positive and coagulase-negative staphylococci. Microb. Drug Resist. 4:119-122.
26. Li, Z., T. Deguchi, M. Yasuda, T. Kawamura, E. Kanematsu, Y. Nishino, S. Ishihara, and Y. Kawada. 1998. Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis. Antimicrob. Agents Chemother. 42:3293-3295.
27. Margerrison, E. E., R. Hopewell, and L. M. Fisher. 1992. Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. J. Bacteriol. 174:1596-1603.
28. Marshall, S. A., W. W. Wilke, M. A. Pfaller, and R. N. Jones. 1998. Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program. Diagn. Microbiol. Infect. Dis. 30:205-214.
29. Montanari, M. P., M. Prenna, M. Mingoia, S. Ripa, and P. E. Varaldo. 1998. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones. Chemotherapy 44:85-93.
30. National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing: 8th informational supplement. M100-S8. National Committee for Clinical Laboratory Standards, Villanova, Pa.
31. National Committee for Clinical Laboratory Standards. 1999. Performance standards for antimicrobial susceptibility testing: 9th informational supplement, p. 37-40. M100-S9. National Committee for Clinical Laboratory Standards. Villanova, Pa.
32. Pegues, D. A., C. Colby, P. L. Hibberd, L. G. Cohen, F. M. Ausubel, S. B. Calderwood, and D. C. Hooper. 1998. The epidemiology of resistance to ofloxacin and oxacillin among clinical coagulase-negative staphylococcal isolates: analysis of risk factors and strain types. Clin. Infect. Dis. 26:72-79.
33. Rupp, M. E. 1997. Infections of intravascular catheters and vascular devices, p. 379-399. In J. B. Crossley and G. L. Archer (ed.), The staphylococci in human disease. Churchill Livingstone, New York, N.Y.
34. Schmitz, F. J., B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, Klootwijk, J. Verhoef, A. Fluit, H. P. Heinz, K. Kohrer, and M. E. Jones. 1998. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrfl in 116 unrelated clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 41:481-484.
35. Soussy, C. J., H. Chardon, H. Drugeon, M. D. Kitzis, A. Phippon, and P. Courvalin. 1998. In vitro antibacterial activity of trovafloxacin against hospital isolates and determination of breakpoints: a multicenter study, abstr. E-28, p. 175. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
36. Sreedharan, S., L. R. Peterson, and L. M. Fisher. 1991. Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. 35:2151-2154.
37. Takahashi, H., T. Kikuchi, S. Shoji, S. Fujimura, A. B. Lutfor, Y. Tokue, T. Nukiwa, and A. Watanabe. 1998. Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 41:49-57.
38. Takahata, M., M. Yonezawa, S. Kurose, N. Futakuchi, N. Matsubara, Watanabe, and H. Narita. 1996. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 38:543-546.
39. Tanaka, M., Y. Onodera, Y. Ushida, K. Sato, and I. Hayakawa. 1997. Inhibitory activities of quinolones against gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob. Agents Chemother. 41:2362-2366.
40. Tang, J. Personal communication.
41. Wang, T., M. Tanaka, and K. Sato. 1998. Detection of gyrA and grlA mutations in 344 Staphylococcus aureus strains. Antimicrob. Agents Chemother. 42:235-240.
42. Weinstein, M. P., S. Mirrett, L. Vanpelt, M. Mckinnon, B. L. Zimmer, W. Kloos, and L. B. Reller. 1998. Clinical importance of identifying coagulase-negative staphylococci isolated from blood cultures - evaluation of microscan rapid and dried overnight gram-positive panels versus a conventional reference method. J. Clin. Microbiol. 36:2089-2092.
43. Yonezawa, M., M. Takahata, N. Banzawa-Futakuchi, N. Matsubara, Y. Watanabe, H. Narita, T. Matsunaga, H. Igarashi, M. Kawahara, and S. Onodera. 1996. DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Staphylococcus haemolyticus. Antimicrob. Agents Chemother. 40: 1065-1966.